Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

18th Annual BIO CEO & Investor Conference

January 12, 2016

Anavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer’s Disease Patients

January 11, 2016

New Alzheimer’s Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, Tolerability and Maximum Tolerated Dose finding in mild-to-moderate Alzheimer’s Patients.

January 11, 2016

Anavex Issues Statement Addressing Recent Press Releases by Law Firms

January 8, 2016

Anavex Announces Fiscal 2015 Year-End Financial Results

December 29, 2015

Novel Anti-Seizure Compound ANAVEX 2-73 a Sigma-1 Receptor Agonist in Multiple Seizure Models.

December 11, 2015

American Epilepsy Society Annual Meeting

December 8, 2015

Third Annual MHPAEA Business Roundtable

December 8, 2015

ICV Manhattan 2015

December 8, 2015

Anavex to Present at Third Annual MHPAEA Business Roundtable in Washington, D.C.

December 7, 2015

Anavex Expands Management Team

December 2, 2015

Independent Research Describes ANAVEX 3-71 as Potent Cognitive Enhancer in Alzheimer’s Disease Models

November 30, 2015
1
234567891011121314
…1516171819…
2021222324252627282930313233343536373839404142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top